Cantargia
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Manufacturing
Description
Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-02-21 14:18 | English | 34.5 KB | |||
| 2020-02-21 11:22 |
Notice of extraordinary general meeting in Cantargia AB (publ)
|
English | 186.7 KB | ||
| 2020-02-21 11:22 |
Kallelse till extra bolagsstämma i Cantargia AB (publ)
|
Swedish | 201.7 KB | ||
| 2020-02-19 23:25 |
Cantargia has completed a directed share issue of approximately SEK 410 million
|
English | 262.6 KB | ||
| 2020-02-19 23:25 |
Cantargia har genomfört en riktad nyemission av aktier om cirka SEK 410 miljoner
|
Swedish | 235.8 KB | ||
| 2020-02-14 12:30 |
Cantargia avancerar utvecklingen av CAN04 genom framgångsrik uppskalning av pro…
|
Swedish | 76.9 KB | ||
| 2020-02-14 12:30 |
Cantargia advances development of CAN04 through successful production scale up
|
English | 76.5 KB | ||
| 2019-12-09 13:53 |
Cantargia väljer CAN10 som utvecklingsprojekt inom systemisk skleros och myokar…
|
Swedish | 119.0 KB | ||
| 2019-12-09 13:52 |
Cantargia selects CAN10 as development project in systemic sclerosis and myocar…
|
English | 140.4 KB | ||
| 2019-12-02 10:30 |
Cantargia reports positive interim data from ongoing phase IIa combination stud…
|
English | 149.5 KB | ||
| 2019-12-02 10:30 |
Cantargia rapporterar positiva interimsdata från pågående fas IIa-kombinationss…
|
Swedish | 128.8 KB | ||
| 2019-11-25 15:00 |
Cantargia AB: Nomination Committee appointed ahead of 2020 Annual General Meeti…
|
English | 20.6 KB | ||
| 2019-11-25 15:00 |
Cantargia AB: Valberedning utsedd inför årsstämman 2020
|
Swedish | 40.1 KB | ||
| 2019-11-18 08:30 |
Cantargia presents novel preclinical data on antibody CAN04 at PEGS Europe conf…
|
English | 111.9 KB | ||
| 2019-11-18 08:30 |
Cantargia presenterar nya prekliniska data runt antikroppen CAN04 på PEGS Europ…
|
Swedish | 112.5 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cantargia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
